Ipriflavone

Research use only, not for human use.

Ipriflavone (7-Isopropoxyisoflavon) is used to inhibit bone resorption.

Ipriflavone (7-Isopropoxyisoflavon) is used to inhibit bone resorption.(In Vitro):Ipriflavone inhibits the proliferation and DNA synthesis of MDA-231 cells and blocks the ligand-induced phosphorylation of Tyr(845) of the EGFR. Ipriflavone does not promote apoptosis of MDA-231 cells. Ipriflavone also promotes the deposition of calcium and the formation of mineralized nodules by newborn rat calvarial osteoblast-like cells as well as the activity of alkaline phosphatase. (In Vivo):Daily oral administration of ipriflavone at 12 mg/mouse significantly inhibits the development of new osteolytic bone metastases and the progression of established osteolytic lesions, prolonging the life of tumor-bearing mice. Ipriflavone reduces the number of osteoclasts at the bone-cancer interface with no severe adverse effects on the host. 1-month treatment with ipriflavone increases bone density and improves the biomechanical properties of adult rat male bones without altering mineral composition.

——

——

Osteofix

Others

Other Targets

advanced glycation end products

Other Indications

——

35212-22-7

280.32

C18H16O3

>98% (HPLC)

Ethanol: 2 mg/mL (7.13 mM); DMSO: 56 mg/mL (199.77 mM)

O=C1C(C2=CC=CC=C2)=COC3=CC(OC(C)C)=CC=C13

7-isopropoxy-3-phenyl-4H-chromen-4-one

(-20℃)

With Ice Pack

≥ 2 years